Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 12/20 | 0.55 |
| ▸ | MMP2 | P08253 | 12/20 | 0.55 |
| ▸ | MMP1 | P03956 | 10/20 | 0.55 |
| ▸ | MMP3 | P08254 | 5/20 | 0.55 |
| ▸ | MMP14 | P50281 | 2/20 | 0.55 |
| ▸ | MMP8 | P22894 | 9/20 | 0.53 |
| ▸ | MMP7 | P09237 | 3/20 | 0.52 |
| ▸ | MMP12 | P39900 | 2/20 | 0.52 |
| ▸ | MMP13 | P45452 | 2/20 | 0.52 |
| ▸ | FCER2 | P06734 | 3/20 | 0.51 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552469 | 1.00 | MMP9 (0.55) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5556724 | 0.92 | MMP9 (0.43) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5557334 | 0.88 | MMP9 (0.60) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5556570 | 0.88 | MMP9 (0.60) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5556574 | 0.88 | MMP9 (0.60) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5552447 | 0.79 | MMP9 (0.74) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5552444 | 0.79 | MMP9 (0.74) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5552386 | 0.78 | MMP9 (0.54) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5552389 | 0.78 | MMP9 (0.54) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5552917 | 0.78 | MMP9 (0.54) | MMP9MMP2MMP1MMP3MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | MMP9 182/4885MMP2 85/4885MMP1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.